Roka Bioscience (NASDAQ: ROKA) is one of 211 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Roka Bioscience to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, dividends, earnings and analyst recommendations.

Risk and Volatility

Roka Bioscience has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Roka Bioscience’s competitors have a beta of 1.50, meaning that their average stock price is 50% more volatile than the S&P 500.

Valuation & Earnings

This table compares Roka Bioscience and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Roka Bioscience $7.24 million -$30.78 million -0.08
Roka Bioscience Competitors $222.84 million -$39.74 million -67.73

Roka Bioscience’s competitors have higher revenue, but lower earnings than Roka Bioscience. Roka Bioscience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

66.5% of Roka Bioscience shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 29.2% of Roka Bioscience shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Roka Bioscience and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Roka Bioscience -507.03% -99.15% -54.56%
Roka Bioscience Competitors -4,025.90% -123.29% -44.71%

Analyst Recommendations

This is a breakdown of current ratings for Roka Bioscience and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roka Bioscience 0 0 1 0 3.00
Roka Bioscience Competitors 486 2383 6484 122 2.66

Roka Bioscience currently has a consensus target price of $10.00, suggesting a potential upside of 809.09%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.33%. Given Roka Bioscience’s stronger consensus rating and higher possible upside, research analysts plainly believe Roka Bioscience is more favorable than its competitors.


Roka Bioscience beats its competitors on 9 of the 12 factors compared.

Roka Bioscience Company Profile

Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Receive News & Stock Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related stocks with our FREE daily email newsletter.